Market Overview - The Shanghai Composite Index fell by 0.64% on January 13, with six industries experiencing gains, led by the oil and petrochemical sector (up 1.62%) and the pharmaceutical and biotechnology sector (up 1.21%) [1] - The defense and military industry and the electronics sector saw the largest declines, down 5.50% and 3.30% respectively [1] Capital Flow Analysis - The net outflow of capital from the two markets was 162.743 billion yuan, with only four industries seeing net inflows [1] - The pharmaceutical and biotechnology sector had the highest net inflow of capital at 4.348 billion yuan, followed by the oil and petrochemical sector with a net inflow of 586 million yuan [1] - The electronics industry experienced the largest net outflow, totaling 37.010 billion yuan, followed by the computer industry with a net outflow of 23.107 billion yuan [1] Pharmaceutical and Biotechnology Sector Performance - The pharmaceutical and biotechnology sector rose by 1.21%, with a total of 478 stocks in the sector, of which 329 stocks increased in value and 16 stocks hit the daily limit [2] - A total of 256 stocks in the sector saw net capital inflows, with 21 stocks receiving over 100 million yuan in net inflows; leading was Mindray Medical with a net inflow of 372 million yuan [2] - The stocks with the highest net outflows included Hainan Haiyao, Huahai Pharmaceutical, and Sanbo Brain Science, with net outflows of 204 million yuan, 164 million yuan, and 153 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - Notable gainers included: - Mindray Medical: up 0.09% with a capital flow of 371.57 million yuan [3] - International Medical: up 9.96% with a capital flow of 290.33 million yuan [3] - Haiwang Biological: up 9.97% with a capital flow of 242.73 million yuan [3] - Boji Pharmaceutical: up 19.96% with a capital flow of 241.23 million yuan [3] - Erkang Pharmaceutical: up 19.95% with a capital flow of 237.43 million yuan [3] Top Losers in Pharmaceutical Sector - Notable losers included: - Hainan Haiyao: down 4.82% with a capital outflow of 203.78 million yuan [5] - Huahai Pharmaceutical: down 3.60% with a capital outflow of 163.67 million yuan [5] - Sanbo Brain Science: down 3.93% with a capital outflow of 153.22 million yuan [5] - Xiangrikui: down 5.49% with a capital outflow of 147.26 million yuan [5] - Luyan Pharmaceutical: down 3.74% with a capital outflow of 110.10 million yuan [5]

Group 1 - The core point of the article is that Yunnan International Trust Co., Ltd. plans to reduce its stake in Hainan Haiyao Co., Ltd. by selling up to 12,973,651 shares, which represents 1% of the company's total share capital [1] Group 2 - The share reduction will occur through centralized bidding transactions within 90 calendar days, starting 15 trading days after the announcement [1]

Core Viewpoint - Hainan Haiyao's innovative drug project, Paengabine, has successfully completed Phase IIa clinical trials, showing promising results for treating refractory epilepsy [1] Group 1: Clinical Trial Results - The Phase IIa clinical trial for Paengabine, developed in collaboration with the Shanghai Institute of Materia Medica, has met both primary and secondary clinical endpoints [1] - The drug, a new generation KCNQ potassium channel agonist, is the first of its kind globally and is intended for the treatment of refractory epilepsy [1] - Initial exploratory efficacy indicators suggest that Paengabine can effectively reduce the frequency of seizures in patients with focal epilepsy after 8 weeks of continuous use [1] Group 2: Regulatory and Development Milestones - Paengabine received approval for clinical trials from the National Medical Products Administration and has completed Phase I trials in healthy subjects [1] - The Phase IIa trial was designed as a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of Paengabine in patients with focal epilepsy [1] - The trial results indicate that Paengabine has good safety and tolerability profiles, with overall risks being manageable [1]

Core Viewpoint - Yunnan International Trust Co., Ltd. plans to reduce its stake in Hainan Haiyao Co., Ltd. by up to 12,973,651 shares, representing 1% of the company's total share capital, within 90 days after the announcement [2] Group 1 - Hainan Haiyao announced that Yunnan International Trust holds 68,295,512 shares, which is 5.26% of the total share capital [2] - The share reduction will occur through centralized bidding transactions [2] - The reduction period is set for 15 trading days after the announcement, lasting for 90 calendar days [2]

Core Viewpoint - On January 9, a total of 20 listed companies disclosed plans for share reductions, with no companies announcing share increases on the same day [1][3]. Group 1: Companies Planning to Reduce Shares - Yihua Tong: Shareholder Zhou Zhuqing plans to reduce no more than 0.02% of shares [2]. - Tongda Electric: Shareholders plan to reduce company shares [2]. - *ST Shengxun: Shareholder Liu Mengran and his concerted parties plan to reduce 2.04% and 2.64% of shares respectively [2]. - Hainan Haiyao: Shareholder Yunnan International Trust plans to reduce no more than 1% of shares [2]. - Goldwind Technology: Shareholder Xinjiang Energy plans to reduce no more than 0.2451% of shares [2]. - Haishun New Materials: Shareholders plan to reduce no more than 0.87% of shares [2]. - Kema Technology: Employee strategic placement asset management plan plans to reduce no more than 0.3528% of shares [2]. - Zhongya Co.: Some executives plan to reduce shares [2]. - Baibang Technology: Director Chen Jin plans to reduce no more than 0.14% of shares [2]. - Yaxiang Co.: Shareholder Zhou Junfang plans to reduce no more than 0.22% of shares [2]. - Dingjie Zhizhi: The largest shareholder, Industrial Fulian, has cumulatively reduced 0.66% of shares [2]. - Hehui Optoelectronics: Shanghai Integrated Circuit Fund plans to reduce no more than 2% of shares [2]. - Heyuan Gas: Changjiang Capital has reduced its holdings to below 5% [2]. - Huati Technology: The actual controller plans to reduce no more than 3% of shares [2]. - Qingyuan Co.: A concerted party of the controlling shareholder plans to reduce no more than 0.17% of shares [2]. - Yongxing Co.: Shareholder Chengtou Investment Company plans to reduce no more than 1.042% of shares [2]. - Jiachih Technology: Shareholder Wen Congyingxi plans to reduce no more than 2.5% of shares [2]. - Western Gold: The third largest shareholder, Jinyuan Company, plans to reduce no more than 1% of shares [2]. - Meirui Mining: Shareholder Li Jian plans to reduce no more than 1% of shares [2]. - Jiankai Technology: Shareholder Wu Kaiti plans to reduce no more than 3% of shares [2].

Core Viewpoint - Hainan Haiyao's subsidiary has successfully completed Phase IIa clinical trials for the innovative drug Paenagabin, which shows promise as a new treatment for refractory epilepsy [1] Group 1: Clinical Trial Results - The Phase IIa clinical trial for Paenagabin has met both primary and secondary clinical endpoints [1] - Paenagabin is classified as a Class 1 chemical drug and is a novel anti-epileptic medication, specifically a next-generation KCNQ potassium channel activator [1] - Currently, there are no marketed products globally for Paenagabin, indicating a unique market opportunity [1] Group 2: Future Development - The completion of Phase IIa is only a preliminary step; further Phase IIb and III clinical trials are required before seeking approval from the National Medical Products Administration for market entry [1] Group 3: Shareholding Changes - Yunnan International Trust plans to reduce its holdings in Hainan Haiyao by up to 12.9737 million shares, representing 1% of the company's total share capital [1]

Core Viewpoint - Yunnan International Trust Co., Ltd. - Ju Li No. 36 Trust, a shareholder holding more than 5% of Hainan Haiyao, plans to reduce its stake by up to 12.97 million shares, representing 1% of the company, due to funding needs [1] Summary by Category - **Shareholder Information** - Yunnan International Trust Co., Ltd. - Ju Li No. 36 Trust holds 68.2955 million shares, accounting for 5.26% of Hainan Haiyao [1] - **Reduction Plan** - The trust intends to reduce its holdings through centralized bidding within 90 natural days, starting 15 trading days after the announcement [1] - The maximum number of shares to be reduced is 12.9737 million [1] - **Source of Shares** - The shares to be reduced were acquired through a tender offer [1] - **Pricing Mechanism** - The reduction price will be determined based on the market price at the time of the sale [1]

证券代码：000566 证券简称：海南海药 公告编号：2026-003 海南海药股份有限公司 关于创新药派恩加滨片Ⅱa 期临床试验研究结果的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）全资子公司海口市制药厂有限 公司与中国科学院上海药物研究所联合研究开发的创新药派恩加滨项目，于近日 完成了Ⅱa 期临床试验，初步研究结果显示达到主要及次要临床终点。 派恩加滨属于化药 1 类，为新型抗癫痫药物，新一代 KCNQ 钾通道激动剂， 目前全球尚无上市品种，本品可用于难治性癫痫的治疗。 一、药物基本情况 药物临床试验批准：国家药品监督管理局核准签发药物临床试验批件 （2018L03179、2018L03180），同意开展临床试验。 二、研发情况及进展 派恩加滨片获得国家药品监督管理局的药物临床试验批准后，海口市制药厂 有限公司已在健康受试者中完成 I 期临床试验，并于 2023 年启动了"评价派恩 加滨片添加治疗局灶性癫痫患者多次口服给药后的安全性、耐受性、有效性和药 代动力学特征的随机、双盲、安慰剂对照、剂量递增的Ⅱa 期 ...

证券代码：000566 证券简称：海南海药 公告编号：2026-004 海南海药股份有限公司 关于持股 5%以上股东减持股份的预披露公告 公司持股 5%以上股东云南国际信托有限公司－聚利 36 号单一资金信托保证 向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有海南海药股份有限公司（简称"本公司"）股份 68,295,512 股（占本 公司总股本比例 5.26%）的股东云南国际信托有限公司－聚利 36 号单一资金信 托（简称"云南国际信托"）计划在本公告披露之日起 15 个交易日后的连续 90 个自然日内以集中竞价交易方式减持本公司股份不超过 12,973,651 股，占本公 司总股本的 1%。 一、减持主体的基本情况 （一）云南国际信托拟减持的具体安排 3、减持方式：集中竞价交易方式。 4、减持股份数量及比例：通过集中竞价交易减持不超过 12,973,651 股，占 本公司总股本比例 1%。在本次减持计划期间内若公司有送股、资本公积金转增 股本等股份变动事项，则对该减持数量进行相应调整。 1 ...

Group 1 - Yunnan International Trust plans to reduce its stake in Hainan Haiyao by up to approximately 12.97 million shares, which represents 1% of the company's total share capital [1] - The reduction will occur through centralized bidding transactions within 90 calendar days after the announcement, starting 15 trading days from the date of the announcement [1] - Yunnan International Trust currently holds about 68.3 million shares, accounting for 5.26% of Hainan Haiyao's total share capital [1] Group 2 - The announcement comes amid a broader context where over 20 provinces have revealed their mechanism electricity prices, with Shanghai's prices being 84% higher than Shandong's and Zhejiang's prices 31% higher than Liaoning's [1] - Experts suggest that there is still room for reduction in enterprise electricity costs [1]